A Study Of Somatostatin On Alpha-cell Secretion

Overview

About this study

The purpose of this study is to determine the effect of somatostatin on AA-stimulated glucagon and oxyntomodulin secretion.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

General Inclusion Criteria:

  • Aged between 25 and 70 years of age

  • Reside within a 100-mile radius of Mayo Clinic, Rochester, MN

Study Groups

  • Group 1 (Obese + IFG): 

    • BMI > 28 Kg/M2 and < 40 Kg/M2

    • Impaired Fasting Glucose (IFG – fasting glucose >100 but <126 mg/dL)

  •  Group 2 (Control group/Lean):

    • BMI > 19 Kg/M2 and < 25 Kg/M2

    • Fasting glucose < 100mg/dL

  • Group 3 (T1DM):

    • BMI > 28 Kg/M2 and < 40 Kg/M2

    • Type 1 diabetes (T1DM)

  •  Group 4 (Obese + NFG) :

    • BMI > 28 Kg/M2 and < 40 Kg/M2

    • Fasting glucose < 100mg/dL

General Exclusion Criteria:

  • Age < 25 (to ensure that we are not studying subjects with latent type 1 diabetes as people in Olmsted County presenting before age 25 have a high incidence of T1DM) or > 70 years (to avoid extreme age as a factor in islet function).

  • Use of any glucose-lowering agents.

  • For female subjects: positive pregnancy test at the time of enrollment or study

  • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.

  • Active systemic illness or malignancy.

  • Symptomatic macrovascular or microvascular disease.

Study Groups

  • Group 1 (Obese + IFG): 

    • BMI < 28 Kg/M2 or > 40 Kg/M2

    • HbA1c > 6.5% or fasting glucose < 100mg/dL or > 126 mg/dL

  • Group 2 (Control group/Lean):

    • BMI < 19 Kg/M2 or > 25 Kg/M2

    • HbA1c > 5.8% or fasting glucose > 100mg/dL

  • Group 3 (T1DM):

    • BMI < 28 Kg/M2 or > 40 Kg/M2

    • HbA1c < 5.8 or > 9.0%

  • Group 4 (Obese + NFG):

  • BMI < 28 Kg/M2 or > 40 Kg/M2

  • HbA1c > 5.8% or fasting glucose > 100mg/dL

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 07/29/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Contact us for the latest status

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions